---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-22-000172"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2022-09-20T23:59:59+00:00"
generated_at: "2026-06-23T08:35:19.931399+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Humacyte appoints Lt. Gen. Bruce Green to board and Cindy Cao as CRO

## Summary
- Green, former U.S. Air Force Surgeon General, joins Board as Class I director.
- Cao appointed Chief Regulatory Officer; prior SVP at Ascentage Pharma and roles at BMS, Novartis.
- Outgoing CRO Bill Tente remains as Executive Advisor on regulatory initiatives.
- Green receives $50K annual cash retainer (pro-rated) and option for 13,000 shares.

## SEC filing metadata
- accession: 0001818382-22-000172
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2022-09-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000172/0001818382-22-000172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000172/huma-20220915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-22-000172
- JSON: https://secwatch.observer/filing/0001818382-22-000172.json
- Plain text: https://secwatch.observer/filing/0001818382-22-000172.txt

## Key facts
- Executive change
  C. Bruce Green was appointed as Director at Humacyte, Inc..
  - Action: appointed
  - Role: Director
  source text: On September 15, 2022, the Board of Directors (the “Board”) of Humacyte, Inc. (the “Company”), appointed C. Bruce Green to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000172/0001818382-22-000172-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.